Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

Inclusion Criteria: * Subject has the ability to understand, able, willing to comply with study procedures and follow up visits, and has provided written consent * Pathologic evidence of solid tumor * Failed standard therapy and deemed by the Investigator to be suitable for participation into the trial * Laboratory values (obtained within 10 days prior to enrollment): ANC: \>= 1.5 × 109/L; Platelets: \>= 100 × 109/L; Hemoglobin: \>= 10.0 g/dL (without transfusions); Bilirubin: within normal range; AST, ALT, and alkaline phosphatase: \<= 2.5 x ULN without tumor liver involvement; Serum creatinine: within normal limits; Calculated creatinine clearance: \>= 60 mL/min/1.73 m2 for patients with creatinine \> Institutional Normal Values; PT/PTT/INR: within normal limits.. * Have IHC evidence of phospho-MET expression on tumor material no more than 12 months old. This is a requirement only for entry into the MTD dose expansion phase. * Have no residual toxic effects of previous therapy, and undergo a washout period of at least 5 half-lives from the time of administration of the previous therapy. Exclusion Criteria: * Pregnant, lactating, or may become pregnant * Cardiac disease requiring medical therapy * Have had a major surgery within 4 weeks prior to Day 1 of the study * Have an active, uncontrolled bacterial, viral, or fungal infection that requires ongoing systemic therapy * Have a known active infection with HIV, hepatitis B or C * Have psychiatric or seizure disorders that would require therapy or interfere with study participation * Have other severe concurrent nonmalignant disease that could compromise protocol objectives, including malabsorptive conditions * Patients receiving prohibited medications as listed in Appendix E, including drugs categorized as strong inhibitors of CYP3A4 and A5 and drugs known to have a high potential risk of liver toxicity * Have known allergy to SGX523 formulation or its excipients (croscarmellose sodium, lactose monohydrate and magnesium steareate) * Patients receiving anti-coagulant therapy